M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 25.68 CNY 0.71% Market Closed
Market Cap: 11.1B CNY
Have any thoughts about
Mayinglong Pharmaceutical Group Co Ltd?
Write Note

Mayinglong Pharmaceutical Group Co Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mayinglong Pharmaceutical Group Co Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
M
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Total Liabilities & Equity
ÂĄ5.2B
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
9%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Liabilities & Equity
ÂĄ33B
CAGR 3-Years
17%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Liabilities & Equity
ÂĄ17B
CAGR 3-Years
16%
CAGR 5-Years
17%
CAGR 10-Years
18%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Liabilities & Equity
ÂĄ48.2B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Liabilities & Equity
ÂĄ54.4B
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
15%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Liabilities & Equity
ÂĄ1.4B
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mayinglong Pharmaceutical Group Co Ltd
Glance View

Market Cap
11.1B CNY
Industry
Pharmaceuticals

Mayinglong Pharmaceutical Group Co., Ltd. engages in the manufacture of pharmaceutical products. The company is headquartered in Wuhan, Hubei and currently employs 3,208 full-time employees. The company went IPO on 2004-05-17. The firm's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The firm also provides specialty drugs. The firm is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The firm distributes its products mainly in domestic markets.

Intrinsic Value
30.62 CNY
Undervaluation 16%
Intrinsic Value
Price
M

See Also

What is Mayinglong Pharmaceutical Group Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
5.2B CNY

Based on the financial report for Sep 30, 2024, Mayinglong Pharmaceutical Group Co Ltd's Total Liabilities & Equity amounts to 5.2B CNY.

What is Mayinglong Pharmaceutical Group Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
9%

Over the last year, the Total Liabilities & Equity growth was 4%. The average annual Total Liabilities & Equity growth rates for Mayinglong Pharmaceutical Group Co Ltd have been 8% over the past three years , 9% over the past five years , and 9% over the past ten years .

Back to Top